| Type | Public |
| HQ | Redwood City, US |
| Founded | 2010 |
| Size (employees) | 139 (est)+10% |
| Website | coherus.com |
Coherus BioSciences was founded in 2010 and is headquartered in Redwood City, US
Report incorrect company information
Viewing summary data as a guest
Sign up for free to see all dataKey People/Management at Coherus BioSciences
Dennis M. Lanfear
President, CEO & Chairman
Alan Herman
Chief Scientific Officer
Jean-Frederic Viret
CFO
Peter Watler
CTO
Vince Anicetti
COO
Michael Fleming
Evp, Corporate and Competitive Strategy & President, Intekrin Therapeutics
Report incorrect company information
Coherus BioSciences Office Locations
Coherus BioSciences has an office in Redwood City
Redwood City, US (HQ)
600 333 Twin Dolphin Dr
Report incorrect company information
Coherus BioSciences Financials and Metrics
Coherus BioSciences Revenue
Coherus BioSciences's revenue was reported to be $1.56 m in FY, 2017
| USD | |
|---|---|
Net income (Q3, 2018) | (58.8m) |
EBIT (Q3, 2018) | (57.0m) |
Market capitalization (17-Jan-2019) | 755.8m |
Closing stock price (17-Jan-2019) | 11.1 |
Cash (30-Sep-2018) | 101.2m |
Coherus BioSciences's current market capitalization is $755.8 m.
Annual
Quarterly
| USD | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 12.4m | 14.1m | |||||||||||
General and administrative expense | 4.0m | 6.1m | 8.8m | 10.2m | 11.4m | 11.3m | 13.6m | 18.8m | 23.5m | 14.0m | 16.6m | 18.4m | 25.4m |
R&D expense | 18.5m | 36.5m | 56.9m | 68.2m | 65.3m | 65.5m | 64.6m | 53.8m | 34.5m | 42.6m | 25.5m | 26.5m | 31.6m |
Operating expense total | 22.5m | 42.6m | 65.8m | 78.4m | 76.7m | 76.8m | 78.2m | 72.6m | 58.0m | 56.6m | 42.0m | 44.9m | 57.0m |
Annual
Quarterly
| USD | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 100.9m | 115.1m | 206.1m | 153.7m | 179.6m | 220.9m | 159.7m | 124.9m | 73.4m | 135.6m | 82.0m | 130.0m | 101.2m |
Current Assets | 118.9m | 143.9m | 239.6m | 189.3m | 211.6m | 236.8m | 177.3m | 208.3m | 153.3m | 171.6m | 112.2m | 172.8m | 130.3m |
PP&E | 3.7m | 5.1m | 6.3m | 8.7m | 10.3m | 9.9m | 10.7m | 14.9m | 14.5m | 13.8m | 11.9m | 11.2m | 6.8m |
Goodwill | 943.0k | 943.0k | 943.0k | 943.0k | 943.0k | 943.0k | 943.0k | 943.0k | 943.0k | 943.0k | 943.0k | 943.0k | 943.0k |
Annual
Quarterly
| USD | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (7.9m) | (40.8m) | (99.9m) | (171.4m) | (65.5m) | (135.7m) | (51.8m) | (74.8m) | (130.2m) | (189.2m) | (44.3m) | (88.0m) | (146.8m) |
Depreciation and Amortization | 632.0k | 1.3m | 717.0k | 1.4m | 2.2m | 865.0k | 1.7m | 2.5m | 922.0k | 1.8m | 2.6m | ||
Accounts Payable | 4.4m | 10.9m | 7.1m | 19.1m | (6.8m) | (7.4m) | (1.6m) | (7.3m) | (3.8m) | (9.2m) | (1.1m) | (2.3m) | (7.8m) |
Cash From Operating Activities | (53.9m) | (113.6m) | (76.3m) | (103.7m) | (165.7m) | (73.3m) | (128.9m) | (170.4m) | (33.6m) | (69.1m) | (111.9m) |
| USD | Y, 2018 |
|---|---|
Financial Leverage | 11.4 x |
Report incorrect company information
Coherus BioSciences Online and Social Media Presence
150 Twitter followers
Coherus BioSciences has 150 Twitter Followers. The number of followers has increased 7.7% month over month and increased 12.8% quarter over quarter
Report incorrect company information
Coherus BioSciences News and Updates
January 07, 2019
Coherus BioSciences Secures $75 Million Credit Financing with HealthCare Royalty Partners
REDWOOD CITY, Calif., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), a commercial biosimilar company, today announced that it has entered into a $75 million senior secured credit facility agreement with Healthcare Royalty Partners.
January 02, 2019
Coherus BioSciences Appoints Darlene Horton, M.D., Chief Medical and Regulatory Affairs Officer
REDWOOD CITY, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the addition of Darlene Horton, M.D. as Chief Medical and Regulatory Affairs Officer. She assumed her role on January 1, 2019.
January 02, 2019
Coherus BioSciences Management to Present at The 37th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at the 37th annual J.P. Morgan healthcare conference on Tuesday, January 8, 2017 at 7:30 a.m. PT being held in San Francisco.
November 20, 2018
Global Behcet Disease Treatment Market Insights by Major Applications, and Top Business Players: AbbVie Inc, Celgene Corp, Coherus BioSciences Inc, Novartis AG, R Pharm, Cell Medica Ltd and other
The Behcet Disease Treatment Market report focuses on the global Behcet Disease Treatment Industry status, future forecast, growth opportunity, key market and key players. Posted via Industry Today. Follow us on Twitter @IndustryToday
November 12, 2018
Coherus BioSciences Management to Present at the 27th Annual Credit Suisse Healthcare Conference
REDWOOD CITY, Calif., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will be presenting at the 27th Annual Credit Suisse Healthcare Conference being held in Scottsdale, Arizona on Thursday, November 15 at 9:45 am MST.
September 25, 2018
Coherus BioSciences Receives European Commission Approval for UDENYCA™ (Pegfilgrastim Biosimilar)
REDWOOD CITY, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the European Commission (EC) has granted marketing authorization to UDENYCA™ (formerly CHS-1701), a pegfilgrastim (Neulasta®) biosimilar. UDENYCA™ is one of the first pegfilgrastim bi…
Report incorrect company information
Coherus BioSciences Company Life and Culture
Report incorrect company information
Coherus BioSciences Frequently Asked Questions
When was Coherus BioSciences founded?
Coherus BioSciences was founded in 2010.
Who are Coherus BioSciences key executives?
Coherus BioSciences's key executives are Dennis M. Lanfear, Alan Herman and Jean-Frederic Viret.
How many employees does Coherus BioSciences have?
Coherus BioSciences has 139 employees.
What is Coherus BioSciences revenue?
Latest Coherus BioSciences annual revenue is $1.6 m.
What is Coherus BioSciences revenue per employee?
Latest Coherus BioSciences revenue per employee is $11.2 k.
Who are Coherus BioSciences competitors?
Competitors of Coherus BioSciences include Sojournix, Tiburio Therapeutics and Casma Therapeutics.
Where is Coherus BioSciences headquarters?
Coherus BioSciences headquarters is located at 600 333 Twin Dolphin Dr, Redwood City.
Where are Coherus BioSciences offices?
Coherus BioSciences has an office in Redwood City.
How many offices does Coherus BioSciences have?
Coherus BioSciences has 1 office.